TransNusa Increases Flight Options For Two Routes From ManadoPT TransNusa Aviation Mandiri converts two chartered flights from Manado to scheduled commercial flightsTickets sale for Manado to Shanghai and Manado to Shenzhen started on July 29, 2025TransNusa continuously expands international route and starts strengthening Manado base in IndonesiaJAKARTA, Aug 11, 2025 - (ACN Newswire via SeaPRwire.com) - FOCUSING on organic growth, TransNusa converts two charter flight routes between Manado and Shanghai as well as Manado and Shenzhen to scheduled commercial routes, starting 8 September and 2 October, respectively.TransNusa Group Chief Executive Officer, Datuk Bernard Francis said while the Manado-Shenzhen scheduled commercial flight is direct, the Manado-Shanghai flight plan has a stop-over of between 30 to 35 minutes at the Clark International Airport.“Our main priority and focus is to create new exciting routes for our passengers and offer seamless and fast travels, whether through direct routes or transits routes.” Datuk Francis said, explaining that the Manado-Clark-Shenzhen route is very popular among tourists.“With the launch of these new commercial routes, we hope to provide tourists from Manado and China additional options to travel,” Datuk Francis said, adding that TransNusa will also provide its passengers with options to visit other major tourist destinations from Manado, such as Bali, also known as Indonesia’s Island of Gods.Details of the new RoutesFrom October 2, TransNusa will be operating three flights a week from Manado’s Sam Ratulangi International Airport to Shenzhen Bao’an International Airport. The TransNusa flight, 8B 175, will depart Manado at 21.10pm and arrive at the Shenzhen Bao’an International Airport at 01.00am while TransNusa flight, 8B 176, will depart Shenzhen Bao’an International Airport at 02.00am and arrive in Manado at 05.50am.TransNusa will be operating the Manado-Shenzhen route three times weekly. The Manado-Shenzhen route scheduled commercial flights are on Tuesday, Thursday and Saturday while the Shenzhen-Manado route scheduled commercial flights will be on Wednesday, Friday and Sunday.TransNusa’s scheduled Manado-Shenzhen flight ticket price starts from as low as IDR3.499.000, CNY1.525 and USD226 while it’s schedule flight from Manado to Shanghai ticket price starts from as low as IDR3.988.000, CNY1.688 and USD257. TransNusa tickets are available for purchase at transnusa.co.id and all other main online travel agent platforms worldwide.Meanwhile, the TransNusa flight, 8B 101, from Manado will depart at 14.00pm and arrive at the Clark International Airport at 16.40pm. The flight will depart Clark International Airport at 17.15pm and arrive at the Shanghai Pudong International Airport at 20.55pm. The flight, 8B 102, will depart the Shanghai Pudong International Airport at 23.05pm and arrive at Clark International Airport at 02.30am. The TransNusa 8B 102, will depart Clark International Airport at 03.00am and arrive at Manado’s Sam Ratulangi International Airport at 05.30am.Datuk Bernard said that TransNusa will operate the six hours 50 minutes scheduled commercial flight route 3 times week. TransNusa’s scheduled commercial flight from Manado will depart on Monday, Wednesday, and Friday.For both the newly introduced scheduled commercial flights, Datuk Bernard said TransNusa will be utilizing its C909 jet airliner, which has only 95 seats, to ensure that passengers travel with comfort.Datuk Bernard Francis…TransNusa offers new flight options for its passengersBrief History On TransNusaTransNusa, which had to close business due to the Covid-19 pandemic was injected with new shareholders and management team in 2022. The airline opened its doors for business in October and within six months, in April 2023, launched its first international flight from Jakarta to Kuala Lumpur, Malaysia.After which, under the new leadership of Datuk Francis, and the new management team, the airline successfully launched three more new international routes by the end of 2023. In 2024, the airline continued growing its international and domestic route and at the same time recording historical firsts that also became a significant industry first for the Indonesian aviation industry. Since April 2023, TransNusa has been making headlines in Malaysia, Singapore, China and around the world with news of being the first airline in Indonesia and the world to develop and introduce a new domestic route connecting Bali and diving haven, Manado. TransNusa also became the second Indonesian airline to receive approval to fly to China and provided Indonesians with more pricing and route options to China.TransNusa’s aggressive international growth strategy combined with its domestic business operations approach has enabled the airline to be the fastest growing airline in South East Asia.About TransNusaTransNusa Airline, is a Premium Service Carrier. After the take-over, in February 2024, the airline rebranded itself from being a Low-Cost Carrier to a Premium Service Carrier in line with its upgraded aircrafts that offers better comfort as well as based on the flexibility and quality of the services offered.TransNusa, which received its AOC certification on 9th September 2022, launch its first three A320 operations on 6th October, 14th October and 12th December, 2022. In 2023, TransNusa introduced a new business model making it the first Premium Service Carrier in the Asia Pacific region. TransNusa introduced its first international flight on 14th April, 2023. The airline is currently has bases in Jakarta, Bali and Manado.The airline currently flies from Jakarta to Yogyakarta, Bali, Kuala Lumpur, Malaysia, Subang, Malaysia and Guangzhou, China. It also flies from Bali to Jakarta and Manado. TransNusa will be launching its scheduled Bali to Perth route on March 20th and its Bali to Guangzhou route on April13th. TransNusa made history when it became the second Indonesian airline to fly to China and the first Indonesian airline to launch a Premium Service Carrier business model.Passengers can book their flights on the TransNusa website (www.transnusa.co.id), through authorized travel agents in Singapore, Malaysia and Indonesia, or by contacting the airline's customer service centre at, +62216310888. For the Singaporean market, passengers can contact TransNusa’s General Sales Agent, Chariot Travels Pte Ltd, at +65 86602719 for assistance.TransNusa’s Primary Media Contact:Trina Thomas Rajtrina@myqaseh.org+60124992672 (watsapp) Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 11, 2025 - (ACN Newswire via SeaPRwire.com) - Cryofocus Medtech (Shanghai) Co., Ltd. ("Cryofocus" or the "Company," Stock Code: 6922.HK), a global innovator in minimally invasive interventional cryotherapy, last friday announced its unaudited interim results for the six months ended June 30, 2025. The Company demonstrated robust growth momentum and significant operational optimization during the reporting period, with key financial metrics delivering exceptional performance. Notably, its respiratory intervention product portfolio fueled a substantial revenue surge, marking accelerated commercialization progress.Respiratory Intervention Products Emerge as Core Growth Engine, Highlighting Global Competitive EdgeThe Company recorded revenue of RMB51.1 million for the first half of 2025, a 162.4% increase from RMB19.5 million in the same period of 2024, setting a new historical high. This growth was primarily attributable to the strategic focus on respiratory intervention products entering a harvest phase: The Malignant Stenosis Cryoablation System, approved by China’s National Medical Products Administration (NMPA) in March 2025, and the previously commercialized Cryoadhesion System, experienced rapid sales expansion, becoming the dominant revenue drivers. Additionally, the distribution partnership with Boston Scientific’s China affiliate, BSC International Medical Trading (Shanghai) Co., Ltd. (“BSC”), contributed significant incremental revenue from other respiratory intervention products in mainland China.Of particular significance, the Company’s Asthma Cryoablation System received "Breakthrough Medical Device" designation from the U.S. Food and Drug Administration (FDA) – the first such international recognition for a Chinese enterprise in the respiratory interventional cryotherapy field – laying a foundation for global market expansion.Cryofocus has established a highly competitive respiratory intervention portfolio addressing critical indications, including malignant stenosis, benign stenosis, asthma, chronic obstructive pulmonary disease (COPD), peri-pulmonary nodules, chronic cough, and airway tuberculosis. Among these: The Malignant Stenosis Cryoablation System has been successfully commercialized in China; systems for asthma and COPD are in confirmatory clinical trials with expected approvals in 2026; products for cough, tuberculosis, and peri-pulmonary nodules are in various R&D stages; and the Cryoadhesion System (including disposable and re-sterilizable cryoprobes) is approved and marketed. These innovations mainly stem from Cryofocus’s two core technology platforms: unique liquid nitrogen-based cryoablation technology (utilizing liquid nitrogen as the cryogenic energy source) and advanced flexible catheter technology. This integrated platform enables deep low-temperature treatment, precise control, and minimally invasive intervention, offering superior therapeutic efficacy and safety while creating significant technological barriers for competitors.Platform Value Multiplies as Multi-Segment Strategy Accelerates CommercializationCryofocus’s core value extends beyond its respiratory pipeline, underpinned by its distinction as an innovative cryotherapy platform enterprise. Leveraging its liquid nitrogen and flexible catheter technologies, the Company has successfully expanded into multiple high-potential therapeutic areas:In the vascular intervention segment: The Atrial Fibrillation (AF) Cryoablation System (for atrial fibrillation treatment) was commercialized in China in September 2024. The Cryofocus Renal Denervation (Cryo-RDN) System (for hypertension treatment), granted FDA Breakthrough Device designation, is in confirmatory clinical trials. The Pulmonary Hypertension Cryoablation System is currently in the stage of pre-clinical study. The market space for all these related cardiovascular indications is very huge.In the Natural Orifice Transluminal Endoscopic Surgery (NOTES) segment: The respiratory intervention portfolio, as detailed, is rich and leading. The cancer intervention portfolio includes the commercialized Bladder Cryoablation System; the Gastric Cryoablation System and Esophageal Cryospray System are in clinical trials targeting gastric and esophageal cancer markets.In non-cryotherapy products: Commercialized items such as the Pulmonary Nodule Localization Needle and Endoscopic Clip for Anastomosis, alongside pipeline products like the Atrial Fibrillation Pulsed Field Ablation (PFA) System and Anti-Gastroesophageal Reflux System, create complementary synergies.This "one-platform, multi-therapy" model endows Cryofocus with exceptional adaptability for indication expansion and pipeline sustainability. The Company currently boasts a robust portfolio of 23 products and candidates: 14 cryotherapy and 9 non-cryotherapy items, with 11 already commercialized. Such platform-based diversification is rare among single-therapy medical device firms, highlighting substantial long-term growth potential and risk resilience.Strong Financial Performance and Sustained Growth MomentumBeyond the revenue surge driven by respiratory products, Cryofocus’s interim results signal positive ongoing growth. The Company’s technological advantages further translated into financial resilience. Gross profit reached RMB34.3 million for the first half of 2025, up 124.5% year-on-year, with a solid gross profit margin of 67.1%. Enhanced R&D efficiency led to significantly reduced losses. R&D expenses optimized to RMB17.9 million (down 51.9% year-on-year), while the period loss narrowed 51.4% to RMB27.2 million, demonstrating a clear trend toward profitability. Cash reserves increased 40.1% from year-end 2024 to RMB63.7 million, providing a solid foundation for sustained R&D and market expansion.Revenue diversification and quality improved as high-value self-developed products (e.g., Malignant Stenosis Cryoablation System) launched and scaled, complemented by deepening collaboration with BSC. The significant reduction in R&D expenses reflects improved efficiency and reduced consumable needs as products advance, driven by optimized personnel costs and management enhancements. This establishes a sound framework for balancing innovation intensity with cost control.Furthermore, the Company increased investment in sales network development, with selling and distribution expenses rising 174.4% year-on-year to RMB9.2 million, underscoring proactive resource allocation to build marketing teams and promote newly launched products (e.g., Malignant Stenosis Cryoablation System), laying groundwork for future sales scale expansion.Global Peer Benchmark Highlights Valuation PotentialCryofocus’s technological strength in respiratory interventional cryotherapy, particularly in FDA-designated areas like asthma treatment, positions it competitively against global leaders.Benchmarked against Inspire Medical Systems (INSP) (focusing on OSA neurostimulation, differing in indication but similar in respiratory neuro-intervention): Inspire currently holds a market capitalization of US$2.279 billion and a trailing-twelve-month (TTM) P/E ratio of 44.28x. Cryofocus’s Asthma Cryoablation System similarly targets pulmonary vagal nerves via minimally invasive ablation, with an innovative pathway validated by FDA Breakthrough status. Yet, as a diversified platform innovator with a broad pipeline and multiple commercialized products, Cryofocus’s current Hong Kong market valuation (Inspire’s market cap is 12.8x Cryofocus’s) significantly trails Inspire’s.This substantial valuation gap, while influenced by factors such as differing markets (US vs. HK), stages of development (Inspire being profitable and established in the US market), and a single-product focus versus a platform model, nonetheless clearly underscores the significant upside potential in Cryofocus Medtech's current market valuation relative to its technological capabilities, the breadth of its product pipeline, and its potential for globalization breakthroughs. With the advancement of clinical progress for its respiratory intervention products (particularly the Asthma Cryoablation System COPD Cryospray System Peri-Pulmonary Nodule Cryoablation System), the clarification of overseas registration pathways, and the continued high-speed growth in its revenue scale, a market re-rating of its value represents a high-probability event. The current valuation level presents an attractive window of opportunity for investors bullish on the long-term prospects of the minimally-invasive interventional cryotherapy sector and the value inherent in a platform company model.Looking ahead, Cryofocus maintains a clear strategy: rapidly advance clinical development and commercialization of pipeline products; deepen focus on minimally invasive interventional cryotherapy while expanding the portfolio leveraging its core platforms; continuously invest in underlying and supporting technologies; and selectively expand global operations. The Company is steadily transitioning from R&D-driven to a dual-engine model integrating R&D and commercialization, advancing resolutely toward its vision of becoming a "global platform for minimally invasive interventional cryotherapy medical devices." Copyright 2025 ACN Newswire via SeaPRwire.com.

香港，2025年8月11日 - (亚太商讯 via SeaPRwire.com) - 专注于微创介入冷冻治疗领域的创新医疗器械公司康沣生物科技（上海）股份有限公司（"康沣生物"或"公司"，股份代号：6922.HK）公布其截至2025年6月30日止六个月的中期业绩。报告期内，公司展现出强劲的增长动能与显著的经营优化，核心财务指标表现亮眼，特别是其呼吸介入产品线实现爆发式增长，标志着公司商业化进程步入快车道。呼吸介入产品成业绩增长核心引擎，全球领先优势凸显公告显示，2025年6月30日止六个月，康沣生物实现收入达人民币5,111万元，较2024年同期1,948万元激增162.4%，创下历史同期新高。这一增长主要源于公司在呼吸介入领域的战略性布局迎来收获期：公司2025年3月获国家药监局批准的恶性狭窄冷冻消融系统及此前上市的冷冻粘连治疗系统等呼吸介入产品销量迅猛增长，成为驱动收入增长的绝对主力；同时，公司与国际医疗巨头波士顿科学的中国附属公司波科国际医疗贸易（上海）有限公司("波科")在其他呼吸介入产品的中国大陆的经销合作也贡献了可观的增量收入。更值得一提的是，公司的哮喘冷冻消融系统获得美国食品及药物管理局授予的"突破性医疗器械"认证 ，成为中国企业在呼吸介入冷冻治疗领域首个获此国际权威认证的产品，为进军全球医疗市场奠定基础。康沣生物在呼吸介入领域构建了极具竞争力的产品矩阵，覆盖从恶性狭窄、良性狭窄、哮喘、慢阻肺（COPD）、肺周结节、慢性咳嗽到气道结核等多种重要适应症。其中：恶性狭窄冷冻消融系统已在中国成功商业化；哮喘、慢阻肺系统处于确证性临床试验阶段，预计2026年获批；咳嗽、结核、肺周结节等系统也处于不同研发阶段；冷冻粘连治疗系统含一次性冷冻探头及可重复使用冷冻探头已获批准并上市。这些产品的成功，主要建立在康沣两大核心技术平台之上--独特的液氮冷冻消融技术（以液氮为冷媒能量源）和先进的柔性导管技术。该平台提供了深低温、精确控制、微创介入的能力，在治疗效率和安全性上具有显著优势，形成了竞争对手难以逾越的技术壁垒。平台价值裂变，多领域布局加速商业化康沣生物的核心价值不仅在于其亮眼的呼吸介入管线，更在于其作为创新型冷冻治疗平台企业的稀缺属性。公司以液氮冷冻技术和柔性导管技术为基石，成功将产品线拓展至多个庞大的治疗领域：其中，在血管介入领域：心脏冷冻消融系统（用于房颤治疗）已于2024年9月在中国商业化。Cryofocus冷冻消融系统（用于高血压治疗）获美国食品及药物管理局"突破性器械"认定，处于确证性临床阶段。肺动脉高压冷冻消融系统处于临床前研阶段。这些产品涉及的心血管适应症市场空间巨大。在经自然腔道内镜手术（NOTES）领域：呼吸介入领域如前所述，产品线丰富且领先。腫瘤介入领域如膀胱冷冻消融系统已在中国上市；胃部冷冻消融系统、食道冷冻喷雾治疗系统处于临床试验阶段，瞄准胃癌、食道癌等市场。在非冷冻治疗产品方面：如肺结节定位针（已上市）、内镜吻合夹（已上市）、房颤脉冲电场消融（PFA）系统、抗胃食管反流系统等，形成互补和协同。这种"一平台、多赛道"模式，赋予了康沣生物极强的适应症扩展能力和管线可持续性。公司目前拥有14款冷冻治疗产品及在研产品，加上9款非冷冻产品，总计23款产品组成的强大管线库，其中11款已实现商业化。这种平台化的布局在专注于单一领域的医疗器械公司中极为罕见，展现了巨大的长期增长潜力和抗风险能力。财务表现优异，成长动能持续除了呼吸介入产品所驱动的收入的高增长，康沣生物中期业绩还透露出积极的持续成长信号。报告期内，公司技术平台的优势进一步转化为财务韧性。2025年6月30日止六个月，康沣生物毛利达3,431万元，同比增长124.5%；毛利率保持在稳健的67.1%。研发效率提升，亏损显著改善。数据显示其研发开支优化至1,791万元（同比下降51.9%），期内亏损收窄至2,722万元，同比缩减51.4%，扭亏趋势明确。现金储备较2024年底增长40.1%至6,368万元，为持续研发和市场拓展提供坚实后盾。随着更多自研高价值产品（如恶性狭窄冷冻消融系统）的上市和放量，以及波科经销合作的深化，公司收入来源更加多元化且质量提升。报告期内，研发费用的大幅下降并非削减投入，而是研发效率提升和部分产品进入后期阶段（减少耗材投入）的结果，员工成本优化和管理改进是关键原因。这为公司未来在维持高强度创新的同时控制成本提供了良好范式。此外，公司在销售网络建设投入也在加大，报告期内销售及分销开支同比增加174.4%至916万元，反映了公司积极投入资源搭建营销团队和推广新上市产品（如恶性狭窄冷冻消融系统），为未来销售规模的进一步扩大奠定基础。对标全球龙头，估值洼地显现康沣生物在呼吸介入冷冻治疗，特别是在获得FDA突破性认证的哮喘治疗等呼吸介入领域的技术实力，使其具备了与国际领先企业同台竞技的潜力。以专注于阻塞性睡眠呼吸暂停（OSA）治疗的神经刺激器企业Inspire Medical Systems（INSP）作为参照（虽然适应症不完全相同，但同属呼吸系统神经介入器械领域）： Inspire Medical目前市值22.79亿美元，市盈率（TTM）44.28倍（根据8月7日收盘价）。康沣生物的哮喘冷冻消融系统同样作用于肺部迷走神经（靶向神经）消融，以微创介入方式治疗哮喘，其技术路径具有创新性且获得了美国食品及药物管理局的突破性认可。然而，作为一家覆盖多领域、拥有丰富管线、且多个产品已商业化的平台型创新公司，康沣生物当前在港股的估值（INSP市值为康沣生物的12.8倍）远低于Inspire Medical的估值水平。这种巨大的估值差异，固然有市场（美股vs港股）、发展阶段（Inspire已盈利且在美国市场成熟）、单一产品vs平台等因素的影响，但也清晰地凸显出康沣生物当前市值与其技术实力、产品管线广度和全球化突破潜力相比，存在显着的提升空间。随着其呼吸介入产品（尤其是是哮喘冷冻消融系统、慢阻肺冷冻喷雾治疗系统、肺周结节冷冻消融系统）临床进展推进、海外注册路径明确以及收入规模的持续高速增长，市场对其价值的重估将是一个大概率事件。当前的估值水平，对于看好微创介入冷冻治疗赛道长期前景和平台型企业价值的投资者而言，提供了一个具有吸引力的布局窗口。展望未来，康沣生物的战略清晰，包括迅速推动在研产品的临床开发和商业化；专注于微创介入冷冻治疗，基于技术平台进一步扩大产品组合；持续研发各种底层技术及配套技术；及选择性地拓展全球业务。公司正稳步从研发驱动向研发与商业化双轮驱动转型，并朝着成为"全球微创介入冷冻治疗医疗器械平台"的愿景坚实迈进。 Copyright 2025 亚太商讯 via SeaPRwire.com.

香港，2025年8月11日 - (亚太商讯 via SeaPRwire.com) - 8月8日，全国首批数据中心REITs--南方润泽科技数据中心REIT与南方万国数据中心REIT正式登陆沪深交易所，上市首日双双涨停，分别报收5.850元和3.9元。两单产品的亮眼表现，不仅标志着REITs市场正式切入"科技新基建"赛道，也凸显了产业资本在推动算力基础设施证券化中的重要作用。作为两单项目的重要投资方，港股上市公司首程控股（0697.HK）再一次站在了市场关注的风口。通过全资子公司北京首源欣荣投资有限公司，以及旗下管理的北京平准基础设施不动产股权投资基金，首程控股分别投资了南方万国数据中心REIT与南方润泽科技数据中心REIT。这不仅是公司在数据中心领域的又一次精准布局，更是其深耕REITs市场战略版图的最新落子。一、切入"算力底座"，紧抓数字经济新机遇公开资料显示，南方万国数据中心REIT的底层资产为位于昆山花桥的国金数据云计算数据中心，机柜数4192个；南方润泽科技数据中心REIT的底层资产则为位于京津冀国家算力枢纽节点的润泽（廊坊）国际信息港A-18数据中心，机柜数5897个，上架率超99%。两大项目均属于区域核心算力资源，在支撑5G、人工智能、大数据等应用方面具有不可替代的战略价值。业内人士指出，数据中心REITs的推出，意味着公募REITs资产类型首次覆盖到科技创新基础设施领域，有助于推动算力资源高效配置，提升资本市场服务数字经济的能力。二、全链条布局，构建REITs生态闭环事实上，首程控股在REITs领域的布局早已形成全链条覆盖。从2021年作为首批公募REITs的最大战略投资者之一起，公司便围绕"Pre-REITs产业基金培育-平台运营管理-公募REITs退出-战略配售投资"建立了完整的生态体系。截至目前，首程控股REITs基金管理规模已突破300亿元，投资领域覆盖交通枢纽、城市更新、绿色能源、数据中心等多个板块。今年以来，公司相继投资了首农产业园REIT、华夏华电清洁能源REIT，并通过北京平准基金与国寿投资、财信人寿等机构合作，设立目标规模100亿元的平准基础设施基金，进一步夯实在REITs市场的产业资本地位。三、产业资本优势显现，助力市场良性发展作为产业资本，首程控股不仅提供资金，更依托自身在智能基础设施资产管理、运营、整合等方面的能力，为底层资产的运营效率和长期价值提升提供保障。这种"资金+运营"的双重赋能模式，使公司在REITs市场中形成了与单纯财务投资机构的差异化优势。分析人士认为，随着公募REITs市场规模的不断扩容，以及数据中心等新型基础设施的证券化步伐加快，首程控股有望在"科技新基建+REITs"这一新兴交汇赛道上持续受益，并巩固其在行业内的引领地位。Posted by All Way Success Company Limited for Shoucheng Holdings www.shouchengholdings.com [HKSE:0697, FRA:SHVA, OTCPK:SHNHF] Copyright 2025 亚太商讯 via SeaPRwire.com.

HONG KONG, Aug 11, 2025 - (ACN Newswire via SeaPRwire.com) - On August 8, the first batch of data center REITs—Nanfang Range Technology Data Center REIT and Nanfang Wanguo Data Center REIT—officially debuted on the Shanghai and Shenzhen stock exchanges, both hitting the daily price limit on their first day of trading, closing at RMB 5.850 and RMB 3.9, respectively. Their strong performance marked the official entry of the REITs market into the "tech new infrastructure" arena and underscored the important role of industrial capital in driving the securitization of computing power infrastructure.As a key investor in both projects, Shoucheng Holdings Limited (0697.HK) has once again found itself in the spotlight. Through its wholly-owned subsidiary, Beijing Shouyuan Xinrong Investment Co., Ltd., and the Beijing Pingzhun Infrastructure Real Estate Investment Fund under its management, Shoucheng Holdings invested in both Nanfang Wanguo Data Center REIT and Nanfang Range Technology Data Center REIT. This represents not only another precise move in the data center sector but also the latest step in Shoucheng’s broader REITs market strategy.Tapping into the “Computing Power Base” to Capture Digital Economy GrowthAccording to public information, the Nanfang Wanguo Data Center REIT is backed by the Guojin Data Cloud Computing Center in Huaqiao, Kunshan, with 4,192 racks; the Nanfang Range Technology Data Center REIT is backed by the A-18 Data Center at Runze (Langfang) International Information Port, located in the Beijing-Tianjin-Hebei National Computing Hub, with 5,897 racks and an occupancy rate exceeding 99%. Both assets are core regional computing power resources, playing a vital role in supporting 5G, artificial intelligence, and big data applications.Industry experts note that the launch of data center REITs marks the first time that public REITs in China have covered the technology innovation infrastructure segment, facilitating more efficient allocation of computing resources and enhancing the capital market’s ability to serve the digital economy.Full-Chain Deployment: Building a Closed-Loop REITs EcosystemShoucheng’s involvement in the REITs market has long gone beyond single investments. Since becoming one of the largest strategic investors in China’s inaugural public REITs in 2021, the company has built a complete ecosystem covering “Pre-REITs industrial fund incubation — platform operations — public REITs exit — strategic placement investment.”Currently, Shoucheng’s REITs fund management scale exceeds RMB 30 billion, with investments spanning transportation hubs, urban renewal, green energy, and data centers. In 2025 alone, the company has invested in the Sunlon REIT and the Huadian REIT, and through the Beijing Pingzhun Infrastructure Real Estate Investment Fund, partnered with China Life Investment and Caixin Life Insurance to launch a RMB 10 billion Pingzhun Infrastructure Fund, further strengthening its position as a leading industrial capital player in the REITs market.Industrial Capital Advantage: Driving Sustainable Market DevelopmentAs an industrial capital investor, Shoucheng Holdings not only provides funding but also leverages its expertise in asset management, operations, and integration of intelligent infrastructure to enhance both the operational efficiency and long-term value of underlying assets. This “capital + operations” dual empowerment model differentiates the company from pure financial investors in the REITs market.Analysts believe that with the ongoing expansion of China’s public REITs market and the acceleration of securitization in emerging infrastructure such as data centers, Shoucheng Holdings is well-positioned to benefit from the convergence of “new tech infrastructure + REITs” and to consolidate its leadership in the sector.Posted by All Way Success Company Limited for Shoucheng Holdings www.shouchengholdings.com [HKSE:0697, FRA:SHVA, OTCPK:SHNHF] Copyright 2025 ACN Newswire via SeaPRwire.com.